Related Experiment Videos
Suramin as adjuvant therapy with radical prostatectomy
1Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago IL 60612, USA.
The Prostate
|May 1, 1996
Summary
This study explored suramin as an adjuvant therapy for prostate cancer using a rat model. Adjuvant suramin significantly reduced residual tumor weight after prostatectomy, suggesting its potential in post-surgical treatment.
Area of Science:
- Urology
- Oncology
- Pharmacology
Background:
- Suramin is a newer agent for prostate cancer management, potentially acting via growth factor inhibition.
- The adjuvant role of suramin in prostate cancer treatment remains unexplored.
- An orthotopic Dunning AT-3 tumor model in rats was developed to study adjuvant therapy efficacy.
Purpose of the Study:
- To assess the efficacy of adjuvant suramin therapy in controlling residual prostate cancer disease after surgery.
- To evaluate the Dunning AT-3 tumor model for assessing adjuvant therapies post-prostatectomy.
Main Methods:
- Orthotopic implantation of Dunning AT-3 tumor cells into rat prostates.
- Surgical prostatectomy was performed 10-12 days post-inoculation.
- Post-operative treatment groups included controls, prostatectomy alone, prostatectomy plus suramin, and prostatectomy plus cytoxan.
Main Results:
- All treatment groups showed a significant reduction in residual disease compared to untreated controls.
- Adjuvant suramin (300mg/Kg) and cytoxan (50 mg/Kg) significantly reduced residual tumor weight post-prostatectomy.
- Mean residual tumor weights were: controls (20 gms), prostatectomy only (6.7 gms), prostatectomy + suramin (2.7 gms), and prostatectomy + cytoxan (2.2 gms).
Conclusions:
- Prostatectomy effectively reduced residual disease in the Dunning AT-3 rat model.
- Adjuvant therapy with suramin or cytoxan further diminished residual disease after prostatectomy.
- The orthotopic Dunning tumor model is suitable for evaluating adjuvant suramin therapy in prostate cancer management.